GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: HX-008 | HX008 | Puyouheng®
pucolentimab is an approved drug
Compound class:
Antibody
Comment: Pucolentimab (formerly HX008) is an anti-PD-1 immune checkpoint inhibitor monoclonal antibody [2]. It blocks interactions between PD-1 and its ligands PD-L1 and PD-L2, and this reactivates a T cell-mediated antitumour response. Pucolentimab has negligible binding to Fc-gamma receptors (FcγRIIIa) or or C1q and therefore exhibits minimal ADCC and CDC activity [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
Classification  |
|
| Compound class | Antibody |
| Ligand families/groups | Immune checkpoint modulators |
| Approved drug? | Yes. China NMPA (2022) |
| International Nonproprietary Names |
|
| INN number | INN |
| 11561 | pucotenlimab |
| Synonyms |
| HX-008 | HX008 | Puyouheng® |
| Database Links |
|
| GtoPdb PubChem SID | 513757571 |
| Search PubMed clinical trials | pucotenlimab |
| Search PubMed titles | pucotenlimab |
| Search PubMed titles/abstracts | pucotenlimab |
